Table 1 Type 1 diabetes-associated protein level changes in the discovery cohort using LonGP. LonGP terms refers to changes associated to the time of seroconversion (“sero”), changes associated to the time of type 1 diabetes diagnosis (“t1d”) or protein level differences observed between the three study groups (“group” and “group × age”). To consider the effect as statistically significant, the explained variation of the effect was required to be > 1%. Selected candidates for the SRM analysis are indicated in the last column. ^aCD5L was selected for SRM analysis on the basis of its known association with IGHM and the similarity between the individual specific protein profiles of CD5L and IGHM.

Q07954

LRP1

Prolow-density lipoprotein receptor-related protein 1

–

"Sero"

21.4

–

P01591

IGJ

Immunoglobulin J chain

–

"Sero"

16.1

x

P06727

APOA4

Apolipoprotein A-IV

–

"Sero"

15.2

x

P20851

C4BPB

C4b-binding protein beta chain

–

"Sero"

6.0

–

P35443

THBS4

Thrombospondin-4

–

"Sero"

4.9

–

P02774

GC

Vitamin D-binding protein

–

"Sero"

4.4

x

P08519

LPA

Apolipoprotein(a)

8.7

"Sero"

4.3

x

P04075

ALDOA

Fructose-bisphosphate aldolase A

–

"Sero"

3.4

–

P43121

MCAM

Cell surface glycoprotein MUC18

–

"Sero"

2.9

–

P02765

AHSG

Alpha-2-HS-glycoprotein

–

"Sero"

2.3

–

P49747

COMP

Cartilage oligomeric matrix protein

–

"Sero"

2.0

–

P18065

IGFBP2

Insulin-like growth factor-binding protein 2

47.7

"Sero"

1.7

x

P02787

TF

Serotransferrin

–

"Sero"

1.4

x

P00748

F12

Coagulation factor XII

–

"Sero"

1.2

x

P54108

CRISP3

Cysteine-rich secretory protein 3

–

"t1d"

3.9

x

P02654

APOC1

Apolipoprotein C-I

–

"t1d"

2.1

x

P02746

C1QB

Complement C1q subcomponent subunit B

1.0

"t1d"

2.1

–

P01871

IGHM

Immunoglobulin heavy constant mu

24.2

"Group" and "Age × group"

9.8 and 4.2

x

P01023

A2M

Alpha-2-macroglobulin

–

"Group"

7.8

–

O43866

CD5L^a

CD5 antigen-like

26.5

–

–

x